𝗞𝗜-𝗜𝗦𝗡 𝗘𝗮𝗿𝗹𝘆 𝗖𝗮𝗿𝗲𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿 𝗔𝘄𝗮𝗿𝗱𝘀: 𝗕𝗮𝘀𝗶𝗰 𝗦𝗰𝗶𝗲𝗻𝗰𝗲: 🇵🇹 Sara Patricia Monteiro-Martins 🇨🇳 Shuai-shuai Xie 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗰𝗶𝗲𝗻𝗰𝗲: 🇨🇦 Ping Liu 🇺🇸 @basmeomeo #ISNWCN

USTMA Wrapped 2025 🎉🎉🎉 A year powered by collaboration, community & shared purpose!! We are deeply grateful to our patients, families, clinicians, researchers & advocates who showed what’s possible when a community comes together 🙏🙏 ustma.org

Presented at #KidneyWk: In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. Full VISIONARY phase 3 trial results: nej.md/493Xtza @ASNKidney

Daratumumab is now approved for high risk smoldering myeloma based off #AQUILA: PhIII, Dara vs Obs: - 39 cycles/3yrs of dara - mPFS 63.1% vs 40.8% at years - OS at 5yrs 93% vs 86.9% - 5.7% discontinued dara because of AEs #MedTwitter #HemeTwitter #OncTwitter #mmsm

We often get asked about the value of identifying the specific antigen in MN and how it may be helpful. In this mini-review @AJKDonline we discuss just that by providing specific examples! Hope you find it helpful! @SethiRenalPath @fervenzafernan1 ajkd.org/article/S0272-6386(…

Just out in the Journal of Clinical Oncology! @JCO_ASCO A paradigm changing paper on MGUS and Smoldering Myeloma @FrancescoMaura4 And it’s Open Access!! ascopubs.org/doi/10.1200/JCO… KEY FINDINGS: 1) We identify for the first time myeloma defining genomic events to differentiate biologic premalignancy (genomic MGUS) from biologic malignancy (genomic Myeloma). 2) We find that most of smoldering myeloma and almost all of high risk smoldering myeloma is biologic malignancy with genomic features indistinguishable from active myeloma 3) We show that some myeloma defining genomic events are also associated with high risk of progression resulting in a genomic model of risk stratification of Smoldering Myeloma. 4) We show that combining the genomic model (genomics) with the IMWG2020 model (clone size) provides a better risk stratification than either alone. 5) We provide the code and information where if you have access to sequencing you can run this yourself to determine whether the patient has genomic MGUS or genomic Myeloma This is a major collaborative international effort with top centers and researchers pooling data so we can finally address these important questions. @FrancescoMaura4 @szusmani @Leif_Bergsagel @myelomaMD @DrOlaLandgren @DrKrinaPatel @Myeloma_Doc @Rfonsi1 @DrGarethMorgan1 @MSKCancerCenter @MayoClinic @SylvesterCancer @Perlmutter_CC and more.

NEW Chapter 👉Thrombotic Microangiopathy by Dr. Nattawat Klomjit, Dr. Paolo So, Dr. Jean Hou, Dr. Anuja Java Access the chapter here: bit.ly/ThromboticMicroangiop… @nikkonephro @JeanHouMD @anuja_java #GlomPedia #GlomCon

Congratulations to @basmeomeo for taking the lead on this!! Brilliant initiative by @GlomCon turning complex topics into quick, accessible reads. Beautiful path images by @JeanHouMD & thx @nikkonephro for making the figs look pretty 😊 #GlomPedia